{
    "relation": [
        [
            "Patente citada",
            "US4287188 *",
            "US4590269 *",
            "US4659825 *",
            "US4670424 *",
            "US4724233 *",
            "US4808716 *",
            "GB2134907A *",
            "WO1984004748A2 *"
        ],
        [
            "Fecha de presentaci\ufffdn",
            "29 Jun 1978",
            "29 Mar 1984",
            "6 Ene 1984",
            "19 Sep 1983",
            "21 Abr 1986",
            "25 Abr 1986",
            "",
            "14 May 1984"
        ],
        [
            "Fecha de publicaci\ufffdn",
            "1 Sep 1981",
            "20 May 1986",
            "21 Abr 1987",
            "2 Jun 1987",
            "9 Feb 1988",
            "28 Feb 1989",
            "",
            "6 Dic 1984"
        ],
        [
            "Solicitante",
            "Burroughs Wellcome Co.",
            "Syntex (U.S.A.) Inc.",
            "Ceskoslovenska Akademie",
            "Merck & Co., Inc.",
            "Stichting Rega Vzw",
            "Ceskoslovenska Akademic Ved",
            "",
            ""
        ],
        [
            "T\ufffdtulo",
            "Purine derivatives",
            "Process for preparing the cyclic phosphate ester of substituted 9-(1,3-dihydroxy-2-propoxymethyl)purines",
            "Isomeric O-phosphonylmethyl derivatives of enantiomeric and racemic 9-(2,3-dihydroxypropyl)adenine",
            "Cyclic pyrophosphates of purine and pyrimidine acyclonucleosides",
            "Therapeutical application of phosphonylmethoxyalkyl adenines",
            "9-(phosponylmethoxyalkyl) adenines, the method of preparation and utilization thereof",
            "T\ufffdtulo no disponible",
            "Novel antiviral agents"
        ]
    ],
    "pageTitle": "Patente US5142051 - N-phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases and a ... - Google Patentes",
    "title": "",
    "url": "http://www.google.es/patents/US5142051?hl=es&dq=flatulence",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 5,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042986451.45/warc/CC-MAIN-20150728002306-00266-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 480294067,
    "recordOffset": 480263809,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{16624=Some substituted N-alkyl derivatives of heterocyclic bases exhibit important biological effects. Among them are e.g. theophylline derivatives Diprophyllin\ufffd and Proxyphyllin\ufffd (bronchodilatory effect), guanine derivatives with antiviral activity, such as Zovirax\ufffd, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, (DHPG, nor-2'-deoxyguanosine, BIOLF-62) or 9-(4-hydroxybutyl)guanine (HBG), further adenine derivatives 9-(S)-(2,3-dihydroxypropyl)adenine (DHPA), 3-(adenin-9-yl)-2-hydroxypropanoic acid (AHPA) and its esters, all with antiviral activity (for a review see e.g. M. J. Harnden/Ed/Approaches to Antiviral Agents; Macmillan, London 1985, pp. 101-134). Significant biological effects have been found also for erythro-9-(2-hydroxynonyl)adenine (EHNA), 1-(2-hydroxyethoxymethyl)-5-benzyluracil or 1-(1,3-dihydroxy-2-propoxymethyl)-5-benzyluracil which are specific inhibitors of catabolic enzymes with the possible application in combination chemotherapy of metabolic or malignant diseases.}",
    "textBeforeTable": "Citas de patentes  TABLE 2__________________________________________________________________________Compounds of general formula I. Config- uration YieldB R C(2) Methoda % RF b kc EUp d__________________________________________________________________________Uracil-1-yl H -- 2 52 0,26 0,13 0,82Thymin-1-yl H -- 2 45 0,30 0,22 0,82Cytosin-1-yl H -- 2 47 0,27 0,35 0,706-Methylpurin-9-yl H -- 2 43 0,37 4,66 0,78Guanin-9-yl H -- 2 37 0,12 0,66 0,72Hypoxanthin-9-yl H -- 6 90 0,23 0,74 0,79Adenin-9-yl H -- 2 56 0,22 2,52 0,752-Aminoadenin-9-yl H -- 2 56 0,08 0,42 0,748-Bromoadenin-9-yl H -- 7 45 0,26 2,97 0,782-Aminopurin-9-yl H -- 2 54 0,37 0,42 0,756-Hydrazinopurin-9-yl H -- 2 37 0,22 0,76 0,787-Deaza-8-azaadenin-9-yl H -- 2 65 0,26 3,24 0,857-Deaza-8-azahypoxanthin-9-yl H -- 6 85 0,29 1,59 1,00Uracil-1-yl CH2 OH RS 4 78 0,21 0,72 0,82Cycosin-1-yl CH2 OH S 4 50 0,23 0,24 0,725-Methylcytosin-1-yl CH2 OH S 4 66 0,28 0,35 0,78Thymin-1-yl CH2 OH S 4 55 0,27 0,85 0,825-Fluoruracil-1-yl CH2 OH RS 4 52 0,15 0,27 1,08Guanin-9-yl CH2 OH RS 4 62 0,11 0,50 0,78Guanin-7-yl CH2 OH RS 4 60 0,13 0,54 0,78Adenin-9-yl CH2 OH S 4 64 0,22 2,79 0,75Adenin-9-yl CH2 OH RS 8 65 0,22 2,79 0,75Adenin-3-yl CH2 OH RS 4 75 0,22 .sup. 1,53e 0,75Hypoxanthin-9-yl CH2 OH RS 4 75 0,28 0,72 0,80Hypoxanthin-9-yl CH2 OH S 5 82 0,28 0,72 0,802-Methyladenin-9-yl CH2 OH RS 4 75 0,27 .sup. 1,34f 0,652-Methylthioadenin-9-yl CH2 OH RS 4 70 0,32 .sup. 4,10f 0,662-Aminoadenin-9-yl CH2 OH RS 4 78 0,23 0,87 0,702-Aminoadenin-9-yl",
    "textAfterTable": "* Citada por examinador Otras citas Referencia 1 * De Clercq, et al., Nature, vol. 323, pp. 464 467 (Oct. 2, 1986). 2 De Clercq, et al., Nature, vol. 323, pp. 464-467 (Oct. 2, 1986). 3 * Holy, et al., Nucleic Acids Research, Symposium Series No. 14, 1984, pp. 277 278. 4 Holy, et al., Nucleic Acids Research, Symposium Series No. 14, 1984, pp. 277-278. * Citada por examinador Citada por Patente citante Fecha de presentaci\ufffdn Fecha de publicaci\ufffdn Solicitante T\ufffdtulo US5262531 * 30 Jun 1989 16 Nov 1993 Japan Tobacco, Inc. Process for preparing 2'-deoxy-\u03b2-adenosine US5468752 * 4 Abr 1994 21 Nov 1995 Freeman; William R. Treatment of conditions of abnormally increased",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}